Vimian Group (VIMIAN) Stock Overview
Engages in the animal health business worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
VIMIAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 43.20 |
| 52 Week High | SEK 47.30 |
| 52 Week Low | SEK 31.45 |
| Beta | 1.53 |
| 1 Month Change | 6.88% |
| 3 Month Change | 15.14% |
| 1 Year Change | 21.18% |
| 3 Year Change | 8.05% |
| 5 Year Change | n/a |
| Change since IPO | -46.60% |
Recent News & Updates
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity
Jun 17
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Jun 02Recent updates
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity
Jun 17Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Jun 02Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely
May 15Is Vimian Group (STO:VIMIAN) A Risky Investment?
Mar 05Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem
Feb 21A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
Feb 14
iM3 Acquisition Will Expand Presence In Veterinary Dental Space
Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Dec 16Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%
Aug 31Is Vimian Group (STO:VIMIAN) A Risky Investment?
Aug 17Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 18Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Apr 09Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Feb 13Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Jan 08Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching
Dec 03There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital
Nov 01Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price
Aug 27When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?
Jul 19Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?
May 19Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Apr 04Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Jan 06Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Dec 09Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?
Aug 25We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)
Jun 18Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?
May 19Shareholder Returns
| VIMIAN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 1.0% | -1.6% | -1.0% |
| 1Y | 21.2% | -9.9% | -4.4% |
Return vs Industry: VIMIAN exceeded the Swedish Medical Equipment industry which returned -9.9% over the past year.
Return vs Market: VIMIAN exceeded the Swedish Market which returned -4.4% over the past year.
Price Volatility
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.6% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: VIMIAN has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: VIMIAN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,200 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMIAN fundamental statistics | |
|---|---|
| Market cap | SEK 22.83b |
| Earnings (TTM) | SEK 218.24m |
| Revenue (TTM) | SEK 4.42b |
Is VIMIAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMIAN income statement (TTM) | |
|---|---|
| Revenue | €391.00m |
| Cost of Revenue | €121.10m |
| Gross Profit | €269.90m |
| Other Expenses | €250.60m |
| Earnings | €19.30m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 18, 2025
| Earnings per share (EPS) | 0.037 |
| Gross Margin | 69.03% |
| Net Profit Margin | 4.94% |
| Debt/Equity Ratio | 29.6% |
How did VIMIAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/17 17:20 |
| End of Day Share Price | 2025/07/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vimian Group AB (publ) is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Hassan Al-Wakeel | Barclays |
| Blanka Porkolab | Barclays |